Title :

Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.

Author(s) :

Sesques, P. [Auteur]
Hospices Civils de Lyon [HCL]
Kirkwood, A. A. [Auteur]
University College of London [London] [UCL]
Kwon, M. [Auteur]
Hospital General Universitario "Gregorio Marañón" [Madrid]
Rejeski, K. [Auteur]
Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München [LMU]
Jain, M. D. [Auteur]
H. Lee Moffitt Cancer Center and Research Institute
Di Blasi, R. [Auteur]
Brisou, G. [Auteur]
Gros, F. X. [Auteur]
Le Bras, F. [Auteur]
Bories, P. [Auteur]
Choquet, S. [Auteur]
Rubio, M. T. [Auteur]
Iacoboni, G. [Auteur]
O'reilly, M. [Auteur]
Casasnovas, R. O. [Auteur]
Bay, J. O. [Auteur]
Mohty, M. [Auteur]
Joris, M. [Auteur]
Abraham, J. [Auteur]
Castilla Llorente, C. [Auteur]
Loschi, M. [Auteur]
Carras, S. [Auteur]
Chauchet, A. [Auteur]
La Rochelle, L. D. [Auteur]
Hermine, O. [Auteur]
Guidez, S. [Auteur]
Cony-Makhoul, P. [Auteur]
Fogarty, P. [Auteur]
Le Gouill, S. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Gastinne, T. [Auteur]
Cartron, G. [Auteur]
Subklewe, M. [Auteur]
Locke, F. L. [Auteur]
Sanderson, R. [Auteur]
King‘s College London
Barba, P. [Auteur]
Vall d'Hebron Institute of Oncology [Barcelone] [VHIO]
Houot, R. [Auteur]
Centre Hospitalier Universitaire [Rennes]
Bachy, E. [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]

Journal title :

Journal of Hematology and Oncology

Abbreviated title :

J Hematol Oncol

Volume number :

17

Pages :

61

Publisher :

BMC

Publication date :

2024-08-06

ISSN :

1756-8722

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Autologous anti-CD19 chimeric antigen receptor (CAR) T cells are now used in routine practice for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Severe (grade ≥ 3) cytokine release syndrome (CRS) and immune effector ...
Show more >Autologous anti-CD19 chimeric antigen receptor (CAR) T cells are now used in routine practice for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Severe (grade ≥ 3) cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) are still the most concerning acute toxicities leading to frequent intensive care unit (ICU) admission, prolonging hospitalization, and adding significant cost to treatment. We report on the incidence of CRS and ICANS and the outcomes in a large cohort of 925 patients with LBCL treated with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) in France based on patient data captured through the DESCAR-T registry. CRS of any grade occurred in 778 patients (84.1%), with 74 patients (8.0%) with grade 3 CRS or higher, while ICANS of any grade occurred in 375 patients (40.5%), with 112 patients (12.1%) with grade ≥ 3 ICANS. Based on the parameters selected by multivariable analyses, two independent prognostic scoring systems (PSS) were derived, one for grade ≥ 3 CRS and one for grade ≥ 3 ICANS. CRS-PSS included bulky disease, a platelet count < 150 G/L, a C-reactive protein (CRP) level > 30 mg/L and no bridging therapy or stable or progressive disease (SD/PD) after bridging. Patients with a CRS-PSS score > 2 had significantly higher risk to develop grade ≥ 3 CRS. ICANS-PSS included female sex, low level of platelets (< 150 G/L), use of axi-cel and no bridging therapy or SD/PD after bridging. Patients with a CRS-PSS score > 2 had significantly higher risk to develop grade ≥ 3 ICANS. Both scores were externally validated in international cohorts of patients treated with tisa-cel or axi-cel.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Submission date :

2024-09-06T21:09:23Z
2024-09-18T07:31:53Z